Literature DB >> 24122559

Prediction of the postoperative prognosis of intrahepatic cholangiocarcinoma (ICC): importance of preoperatively- determined anatomic invasion level and number of tumors.

Shigeru Marubashi, Kunihito Gotoh, Hidenori Takahashi, Hiroaki Ohigashi, Masahiko Yano, Osamu Ishikawa, Masato Sakon.   

Abstract

BACKGROUND: Preoperative prediction of the prognosis of patients with intrahepatic cholangiocarcinoma (ICC) following surgical treatment remains quite difficult and controversial. We attempted to identify the preoperative and postoperative predictors of the overall survival rates inpatients with ICC in order to clarify the appropriate indications for surgical resection of ICC. PATIENTS AND METHODS: We retrospectively investigated the clinicopathological features of ICC and outcome of surgical resection in 111 consecutive patients who underwent surgical treatment at our hospital between 1980 and March 2012. Both preoperative factors and operatively confirmed factors were evaluated as potential risk factors for determination of the post-surgical prognosis.
RESULTS: Curative resection (R0) was performed in 72 patients (64.9 %). The 1- and 3-year overall survival rates were 85.0 and 59.7 % in the R0 group. Two preoperative factors [hilar invasion as recognized by computed tomography(HR 3.16, P = 0.020) and multiple intrahepatic tumors (HR 7.09, P = 0.0002)] and two operatively confirmed factors [multiple intrahepatic tumors (HR 9.17,P = 0.0009) and lymph node metastasis as confirmed by final histology (HR 6.41, P = 0.003)] were identified as significant risk factors adversely influencing the overall survival rate after surgery. Furthermore, solitary, small(\5 cm) and peripheral ICCs were associated with a very low probability of lymph node metastasis.
CONCLUSIONS: Preoperatively diagnosed hilar invasion,multiple intrahepatic tumors and histologically confirmed lymph node metastasis were the main determinants of an adverse postoperative prognosis in patients with ICC.Lymph node dissection could be omitted for patients with solitary, small and peripheral ICCs.

Entities:  

Mesh:

Year:  2014        PMID: 24122559     DOI: 10.1007/s10620-013-2894-4

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  46 in total

1.  Adjuvant transcatheter arterial chemoembolization for intrahepatic cholangiocarcinoma after curative surgery: retrospective control study.

Authors:  W F Shen; W Zhong; Q Liu; C J Sui; Y Q Huang; J M Yang
Journal:  World J Surg       Date:  2011-09       Impact factor: 3.352

2.  Clinical parameters predicting survival duration after hepatectomy for intrahepatic cholangiocarcinoma.

Authors:  Bei-ge Jiang; Rui-liang Ge; Liang-liang Sun; Ming Zong; Gong-tian Wei; Yong-jie Zhang
Journal:  Can J Gastroenterol       Date:  2011-11       Impact factor: 3.522

3.  Multicentric evaluation of a clinical and prognostic scoring system predictive of survival after resection of intrahepatic cholangiocarcinomas.

Authors:  Georgios C Sotiropoulos; Masaru Miyazaki; Manousos M Konstadoulakis; Andreas Paul; Ernesto P Molmenti; Ilias P Gomatos; Arnold Radtke; Hideo A Baba; Susanne Beckebaum; Eirini I Brokalaki; Masayuki Ohtsuka; Myron E Schwartz; Christoph E Broelsch; George Sgourakis
Journal:  Liver Int       Date:  2010-02-05       Impact factor: 5.828

4.  Predictive factors for long-term survival in patients with intrahepatic cholangiocarcinoma.

Authors:  T Isa; T Kusano; H Shimoji; Y Takeshima; Y Muto; M Furukawa
Journal:  Am J Surg       Date:  2001-06       Impact factor: 2.565

5.  Prognostic factors after surgical resection for intrahepatic, hilar, and distal cholangiocarcinoma.

Authors:  Yoshiaki Murakami; Kenichiro Uemura; Takeshi Sudo; Yasushi Hashimoto; Akira Nakashima; Naru Kondo; Ryutaro Sakabe; Hiroki Ohge; Taijiro Sueda
Journal:  Ann Surg Oncol       Date:  2010-10-14       Impact factor: 5.344

6.  Intrahepatic cholangiocarcinoma: prognostic factors after surgical resection.

Authors:  Alfredo Guglielmi; Andrea Ruzzenente; Tommaso Campagnaro; Silvia Pachera; Alessandro Valdegamberi; Paola Nicoli; Alessandro Cappellani; Giulio Malfermoni; Calogero Iacono
Journal:  World J Surg       Date:  2009-06       Impact factor: 3.352

7.  Multicenter, phase II study of gemcitabine and S-1 combination chemotherapy in patients with advanced biliary tract cancer.

Authors:  Takashi Sasaki; Hiroyuki Isayama; Yousuke Nakai; Yukiko Ito; Hirofumi Kogure; Osamu Togawa; Nobuo Toda; Ichiro Yasuda; Osamu Hasebe; Iruru Maetani; Naoki Sasahira; Kenji Hirano; Takeshi Tsujino; Minoru Tada; Masao Omata
Journal:  Cancer Chemother Pharmacol       Date:  2009-08-26       Impact factor: 3.333

8.  Clinicopathological prognostic factors and impact of surgical treatment of mass-forming intrahepatic cholangiocarcinoma.

Authors:  Shohachi Suzuki; Takanori Sakaguchi; Yoshihiro Yokoi; Kazuya Okamoto; Kiyotaka Kurachi; Yasuo Tsuchiya; Takuya Okumura; Hiroyuki Konno; Satoshi Baba; Satoshi Nakamura
Journal:  World J Surg       Date:  2002-03-26       Impact factor: 3.352

9.  Prognostic factors in node-negative intrahepatic cholangiocarcinoma with special reference to angiogenesis.

Authors:  Ken Shirabe; Mitsuo Shimada; Eiji Tsujita; Shin-ichi Aishima; Shin-ichiroh Maehara; Sinji Tanaka; Kenji Takenaka; Yoshihiko Maehara
Journal:  Am J Surg       Date:  2004-04       Impact factor: 2.565

10.  Therapeutic value of lymph node dissection during hepatectomy in patients with intrahepatic cholangiocellular carcinoma with negative lymph node involvement.

Authors:  Kazuaki Shimada; Tsuyoshi Sano; Satoshi Nara; Minoru Esaki; Yoshihiro Sakamoto; Tomoo Kosuge; Hidenori Ojima
Journal:  Surgery       Date:  2009-02-23       Impact factor: 3.982

View more
  10 in total

Review 1.  The value of systematic lymph node dissection for intrahepatic cholangiocarcinoma from the viewpoint of liver lymphatics.

Authors:  Yuji Morine; Mitsuo Shimada
Journal:  J Gastroenterol       Date:  2015-04-02       Impact factor: 7.527

2.  Low Incidence of Lymph Node Metastasis After Resection of Hepatitis Virus-Related Intrahepatic Cholangiocarcinoma.

Authors:  Hiroya Iida; Masaki Kaibori; Shogo Tanaka; Shigekazu Takemura; Hiroshi Wada; Fumitoshi Hirokawa; Takuya Nakai; Michihiro Hayashi; Hidetoshi Eguchi; Shoji Kubo
Journal:  World J Surg       Date:  2017-04       Impact factor: 3.352

Review 3.  Review to better understand the macroscopic subtypes and histogenesis of intrahepatic cholangiocarcinoma.

Authors:  Yuichi Sanada; Yujo Kawashita; Satomi Okada; Takashi Azuma; Shigetoshi Matsuo
Journal:  World J Gastrointest Pathophysiol       Date:  2014-08-15

4.  Circulating osteopontin per tumor volume as a prognostic biomarker for resectable intrahepatic cholangiocarcinoma.

Authors:  Kai-Qian Zhou; Wei-Feng Liu; Liu-Xiao Yang; Yun-Fan Sun; Jie Hu; Fei-Yu Chen; Cheng Zhou; Xiang-Yu Zhang; Yuan-Fei Peng; Lei Yu; Jian Zhou; Jia Fan; Zheng Wang
Journal:  Hepatobiliary Surg Nutr       Date:  2019-12       Impact factor: 7.293

5.  The Roles of MicroRNA-122 Overexpression in Inhibiting Proliferation and Invasion and Stimulating Apoptosis of Human Cholangiocarcinoma Cells.

Authors:  Ning Liu; Fan Jiang; Tian-Lin He; Jun-Kuan Zhang; Juan Zhao; Chun Wang; Gui-Xing Jiang; Li-Ping Cao; Peng-Cheng Kang; Xiang-Yu Zhong; Tian-Yu Lin; Yun-Fu Cui
Journal:  Sci Rep       Date:  2015-12-21       Impact factor: 4.379

6.  Precision surgery for primary liver cancer.

Authors:  Takeshi Takamoto; Masatoshi Makuuchi
Journal:  Cancer Biol Med       Date:  2019-08       Impact factor: 4.248

7.  Current survival and treatment trends for surgically resected intrahepatic cholangiocarcinoma in the United States.

Authors:  Ariella M Altman; Scott Kizy; Schelomo Marmor; Jing Li Huang; Jason W Denbo; Eric H Jensen
Journal:  J Gastrointest Oncol       Date:  2018-10

Review 8.  Cholangiocarcinoma: Biology, Clinical Management, and Pharmacological Perspectives.

Authors:  Rocio I R Macias
Journal:  ISRN Hepatol       Date:  2014-02-16

9.  Preoperative metabolic tumor volume of intrahepatic cholangiocarcinoma measured by 18F-FDG-PET is associated with the KRAS mutation status and prognosis.

Authors:  Yoshinobu Ikeno; Satoru Seo; Keiko Iwaisako; Tomoaki Yoh; Yuji Nakamoto; Hiroaki Fuji; Kojiro Taura; Hideaki Okajima; Toshimi Kaido; Shimon Sakaguchi; Shinji Uemoto
Journal:  J Transl Med       Date:  2018-04-11       Impact factor: 5.531

10.  The blockade of interleukin-33 released by hepatectomy would be a promising treatment option for cholangiocarcinoma.

Authors:  Satoshi Nagaoka; Daisaku Yamada; Hidetoshi Eguchi; Yuki Yokota; Yoshifumi Iwagami; Tadafumi Asaoka; Takehiro Noda; Koichi Kawamoto; Kunihito Gotoh; Shogo Kobayashi; Eiji Miyoshi; Yuichiro Doki; Masaki Mori
Journal:  Cancer Sci       Date:  2020-11-24       Impact factor: 6.518

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.